CNBC reveals the 2020 Disruptor 50 list, identifying start-ups on the cutting edge of huge consumer, technology and business shifts — and already worth billions.
The British drugmaker has already begun human trials of the vaccine developed by the University of Oxford, with a phase I trial in Britain due to end soon.
Butterfly Network pioneered a medical imaging device that has revolutionized ultrasound technology and made point-of-care solutions more affordable for all.
CLEAR is a technology company that operates security terminals at US airports and event venues using biometric data, aggregated via the company's proprietary identity platform.
Healthy.io makes a medical device out of your smartphone to make remote urinalysis possible. It specializes in the early diagnosis of chronic kidney disease, urinary tract infections and prenatal testing.
Neteera is a digital health company that uses technology to remotely monitor well-being at home and in the hospital, whether its stress, attention or other vital signs.
Tempus is a health-tech company that uses artificial intelligence to provide physicians with clinical data that can be used to create customized treatments for patients.
Hiring your own plane is one answer to safe travel this summer amid the coronavirus pandemic. As more countries reopen to tourists, here's everything you need to know to charter your first flight.
Mnuchin's statements indicating the Treasury and Small Business Administration would not be disclosing the names of those who took out PPP loans angered high-ranking Democrats.
The Food and Drug Administration warned that taking anti-malaria drug hydroxychloroquine along with antiviral drug remdesivir "may result in reduced antiviral activity" of the latter.
The World Health Organization said Monday that more scientists globally should investigate disease clusters to analyze what is driving infection and causing further spread, in light of China's recent cluster of novel coronavirus cases.
"I think the behaviors that were built in the last several months have the real potential to continue to provide a catalyst for improved results," CEO Mark Clouse said in a "Mad Money" interview.